Background: Rare mutations in genes associated with Mendelian forms of disease are a potential mechanism for sporadic disease. The need to assess the clinical significance of such variants is increasing as personalized medicine and genome sequencing increases.
INTRODUCTION 1 2
Human geneticists are increasingly appreciative of the role of rare variants in disease [1] [2] [3] [4] . A 3 role for novel mutations in genes associated with familial, Mendelian forms of diseases has been 4 Enrichment kit or whole-genome sequenced, and case samples were sequenced using the Agilent 1 All Exon 37MB or 50MB kit, using Illumina GAIIx or HiSeq 2000 or 2500 sequencers 2 according to standard protocols. All samples were processed using the same methods, as follows. 3
The Illumina lane-level fastq files were aligned to the Human Reference Genome (NCBI Build 4 37) using the Burrows-Wheeler Alignment Tool (BWA) [26] . We then used Picard software 5 (http://picard.sourceforge.net) to remove duplicate reads and process these lane-level SAM files, 6 resulting in a sample-level BAM file that is used for variant calling. We used GATK to 7 recalibrate base quality scores, realign around indels, and call variants [27] . Variants were 8 required to have a quality score (QUAL) of at least 20, a genotype quality (GQ) score of at least 9 20, at least 10x coverage, a quality by depth (QD) score of at least 2 and a mapping quality (MQ) 10 score of at least 40. Indels were required to have a maximum strand bias (FS) of 200 and a 11 minimum read position rank sum (RPRS) of -20. SNVs were restricted according to VQSR 12 tranche (calculated using the known SNV sites from HapMap v3.3, dbSNP, and the Omni chip 13 array from the 1000 Genomes Project): the cutoff was a tranche of 99.9%. Variants were 14 excluded if marked by EVS as being failures [28] . Variants were annotated to Ensembl 73 using 15
SnpEff [29] . 16 
17
Only genetically European ethnicity samples were included in the analysis. Samples were 18 screened with KING [30] to remove second-degree or higher relatives; samples with incorrect 19 sexes according to X:Y coverage ratios were removed, as were contaminated samples according 20
to VerifyBamID [31] . 21
22

Statistical and informatic analysis 23
Our study used a gene-based collapsing methodology as previously described [6] . For each gene, 1 each sample was indicated as carrying or not carrying a qualifying variant. Qualifying variants 2 were defined for a dominant model requiring at least one qualifying variant per gene with a 3 minor allele frequency (MAF) cutoff of 0.1% internally and 0.01% in each population of the 4 ExAC database, which has been available for longer than the gnomad database [32] . These allele 5 frequency thresholds used a leave-one-out method for the combined sample of cases and controls 6
(where the MAF of each variant was calculated using all samples except for the sample in 7 question). We performed analyses of CCDS genes using two methods to identify qualifying 8 variants: 1) all non-synonymous and canonical splice variants (coding model), and 2) all 9 canonical splice and non-synonymous coding variants except those predicted by PolyPhen-2 10
HumDiv [33] to be benign (likely gene disrupting model). Qualifying variants were identified 11 using Analysis Tools for Annotated Variants v.6.0 12 (http://redmine.igm.cumc.columbia.edu/projects/atav/wiki). This is an in-house software package 13 maintained by the Institute for Genomic Medicine (IGM) at Columbia University that compiles 14 genotype and quality information on all cases and controls sequenced at the IGM as well as 15 annotation data from sources like Ensembl, Polyphen, and ExAC in an easy to use format. We 16 also downloaded qualifying variants from the ExAC database [32] using the same criteria for the 17 coding and likely gene disrupting models, restricting to variants that pass ExAC QC and 18 requiring MAFs to be below 0.01% in each population of the ExAC database. While individual-19 level data are not available from ExAC, making it impossible to determine exactly how many 20 people had a variant in each gene, we used a conservative estimate by adding up the number of 21 carriers of each rare variant in each gene, and we calculated the proportion of people with a 22 qualifying variant in each gene by assuming that no one had more than one variant in the gene. 23 
1
In addition to comparing the numbers of cases and controls with qualifying variants for each 2 model in each gene, we also performed an aggregate collapsing analysis that compared the 3 number of cases and controls with a qualifying variant in any of the known dystonia genes, 4 considered collectively. 5
6
Candidate dystonia genes were identified as OMIM genes containing the word "dystonia" in the 7
clinical synopsis plus FTL (NBIA3), PANK2 (NBIA1), PLA2G6 (NBIA2), ATN1, HTT, PARK2, 8
TAF1 (DYT3), TOR1A, ARSG, and CIZ1 (n =148 genes). Isolated dystonia genes were those 9 covered in a recent dystonia review (n =14 genes) [9] . Overall, 94.9% (88.7%) of the coding 10 bases had at least 10x coverage in our control (case) samples, indicating that the sequence data 11 would be able to pick up most causal variants in these genes if they existed. There were 7 genes 12 that had <50% of their bases with at least 10x coverage (<50% coverage in cases and controls: 13 ARX, GJC2, and SDHAF1; poor coverage in cases only: TSFM, CACNA1B, CACNA1A, and 14 PDX1). For the aggregate collapsing analysis across all candidate genes, a Fisher's exact test was 15 performed using http://www.langsrud.com/fisher.htm. Power was calculated using the Genetic 16
Power Calculator [34] , with a dystonia prevalence of 1 in 10,000, 80% power, a D-prime of 1, 17 marker allele frequency of 3% (to reflect the frequency of qualifying coding mutations occuring 18 in any of the isolated dystonia genes in the general population) and equal to risk allele frequency, 19
Aa relative risk equal to AA relative risk (dominant model), 20 cases, a control:case ratio of 20 118.6 (for 2,372 controls), and an alpha of 0.05 for the one test of all isolated dystonia genes in 21 aggregate. 22
RESULTS
4
To characterize the prevalence of individuals with genetic variants that could potentially be 5 described as pathogenic in genes associated with dystonia, we first sequenced the exomes of 6 2,372 population controls of European ancestry. We additionally sequenced the exomes of 20 7 patients with sporadic dystonia and of European ancestry, whose clinical characteristics are 8 summarized in Table 1 . 9
Two sets of "dystonia-associated" genes were curated for the analysis. The first is a more 11 stringent set of genes (14 in total) that have been associated with dystonia in isolation from other 12 phenotypes, "isolated dystonia" (reviewed in [9] ). The second set of genes (n=148) more broadly 13 considered those genes in which dystonia had been described as part of the clinical phenotype 14 (see Methods for further details). We first performed a gene-based collapsing analysis where 15 each sample was coded to indicate whether they had a qualifying variant in each sequenced gene. 16 "Qualifying" was defined based on two different genetic models: "coding" and "likely gene 17 disrupting". We then identified the total number of subjects with a qualifying variant in any of 18 the dystonia genes analysed to arrive at the overall frequency. 19 
20
Among the group of isolated dystonia genes, we found that 4.2% of controls had qualifying 21 variants in the coding model and 3.0% in the likely gene disrupting model (Table 2) . At this rate, 22
we would have expected fewer than 1 of the 20 dystonia cases to have qualifying variants in at 23 least one of these genes by chance, and we found that 0 had such variants. Though we only had 1 20 cases, our aggregate analysis across all known isolated dystonia genes had 80% power to 2 identify a signal where at least 15% of sporadic dystonia cases were due to pathogenic or 3 possibly pathogenic coding variants in these genes. 4
5
We then broadened our scope to all genes previously reported as associated with dystonia in 6 OMIM and literature reviews as compared to controls, 148 genes in total. We found that 50.6% 7 of controls had qualifying coding variants in at least one of these genes. The frequency among 8 cases was remarkably similar, 45.0%. For the likely gene disrupting model, qualifying variants 9
were found in 37.1% of controls and again, a similar frequency of 35.0% in cases. 10 
11
Although the primary outcome for this analysis was the aggregated contribution of rare variation 12 in dystonia genes when considered as a group, in Table 3 we also indicate the proportion of cases 13 and controls with qualifying variants for each gene analysed. The dystonia-associated gene that 14 was most often mutated in population controls was DST, with 4.1% of controls having variants in 15 the coding model and 1.6% in the likely gene disrupting model. Additionally, all of the primary 16 dystonia genes had qualifying variants in at least one of our controls under the coding model, 17 while 4.7% of the genes in the extended candidate dystonia gene list were never mutated in this 18 control set. 19 20 Table 3 and S1 Table also present an estimate for the proportion of people in the general 21 population from several ethnicities who have qualifying variants in each of these genes. The data 22 for this section come from the ExAC database, a collection of exome sequence data from 23 >60,000 people at the time of access [32] . Unlike the data presented for our locally sequenced 1 controls, the proportion of carriers of qualifying variants in each ExAC population is an estimate 2 because individual-level data are not available from ExAC; that is, if the same person has two 3 qualifying variants in the same gene, then you will accidentally count them twice. In our locally 4 sequenced controls, we found that 0.5% and 0.9% of controls had more than one qualifying 5 variant in a single candidate dystonia gene under the coding and likely gene disrupting models, 6
respectively. This result indicates that it is uncommon for a person to have multiple qualifying 7 variants in a single candidate dystonia gene, and so the frequency of qualifying variants per gene 8 from ExAC is fairly accurate, which is also supported by the strong similarity between the 9 frequencies of qualifying variants for each gene in our locally sequenced controls and the 10 European ExAC population (S1 Fig and S2 Fig) . However, it is important to note that one cannot 11 use ExAC data to estimate how often a person would have a qualifying mutation in any of the 12 genes, i.e., considered in aggregate. In our controls, 15.5% of individuals had rare qualifying 13 variants in more than one dystonia gene (of the 148 dystonia genes) for the coding model, and 14 8.5% for the likely gene disrupting model. 15 
16
DISCUSSION 18 19
Here, we have performed exome sequencing and evaluated the frequency of individuals with rare 20 variation in previously reported dystonia genes in 2,372 population controls and a pilot sample of 21 20 sporadic dystonia patients. We found that it is fairly common for population controls to have 22 likely gene disrupting variants in these genes. Depending on the variant-calling model used, we 23 found that between 37 and 51% of the control population had qualifying variants in dystonia 1 genes. Among the subset of 14 genes associated with causing only dystonia and not being part of 2 a larger syndrome ("isolated"), we found that 3-4% of the population harbored qualifying 3 variants. These frequencies are noteworthy since dystonia is a rare disease, estimated to affect 4 significantly fewer than 0.1% of the population [35] . Thus, the results of our study provide an 5 important point-of-reference for providers in the clinical setting that are considering the 6 significance of a rare variant found in an individual with dystonia. 7
8
For the purpose of counseling a patient, knowing that there is not a strong enrichment of variants 9 in dystonia genes in sporadic patients promotes using caution when assigning causality to a 10 variant. Based on our analysis, if all individuals with a qualifying rare variant in a dystonia gene 11 were to be clinically considered for the presence of dystonia, at most 1 individual in 2000 12 subjects with rare variants in isolated dystonia genes would be expected to have dystonia based 13 on an estimated clinical incidence of 1 in 10,000 and a frequency of such variants in the general 14 population of 3% (and <15% of sporadic dystonia cases). Conversely, for an individual with 15 clinically confirmed dystonia, the chance that their rare variant is incidental is 1 in 25-33 for 16 isolated dystonia genes and 1 in 2-3 for any dystonia-associated gene. 17 18 
19
A number of isolated cases of sporadic disease have been reported that possess rare, likely gene-20 disrupting mutations in previously described dystonia genes [10-13, 15, 17-19] , and more 21 recently, the collective burden of rare variation has been assessed in single dystonia genes of 22 interest [11, 19, 21, 36] . The present study is the first to formally describe the overall frequency 23 of rare dystonia gene variants. We focused the study on population controls, but also 1 systematically searched for evidence of enrichment in sporadic dystonia cases. Though our case 2 sample size was small, the collapsing nature of this analysis, in which all dystonia genes are 3 considered as a group, was sufficiently powered to ascertain whether a substantial fraction of 4 sporadic dystonia cases (>15% or 3 subjects) could be explained by rare missense variation in 5 isolated dystonia genes. We found no evidence for an enrichment of rare functional variants in 6 dystonia genes among sporadic dystonia patients. Of course, specific variants and/or individual 7 dystonia-associated genes may still play a role in some cases and larger scale studies are 8 necessary to determine their significance. Our study subjects had predominantly adult-onset focal 9 dystonias, while a recent report indicates a potentially larger contribution of rare variants in 10 dystonia genes to early-onset dystonia [37] . Larger scale studies are necessary to determine these 11 possibilities. Our results indicate however, that this genetic mechanism, on its own, is not 12 sufficient to explain the bulk of sporadic cases and emphasize the need for a better understanding 13 of other potential genetic and non-genetic factors that give rise to dystonia in the population with 14 late-onset sporadic presentation. 15
16
We also note that our conclusions specifically apply to rare coding variants and not other sources 17 of genetic variation. For example, exome sequencing does miss many insertions and deletions as 18 well as structural variants and non-coding variants. Causal variants in some of the known 19 dystonia genes, such as the intronic retrotransposon insertion in TAF1 (DYT3) [38] and some of 20 the larger deletions in SGCE [39, 40] , cannot therefore be accurately screened in our study. 21
Finally, we present the approximate rate at which controls in the ExAC database have rare 1 coding variants in dystonia genes (Table 3 and S1 Table) . These numbers are approximate 2 because individual-level data are not available from databases like ExAC and gnomad, and thus 3
is actually only 50.5% who have a mutation in at least one of these genes. As a final caveat, all 10 sequencing data sets have their own particular parameters in terms of, for example, the kit used, 11 the sequencing quality, the processing software used, and the quality and annotation cutoffs used 12 to identify variants of interest. It is therefore imprecise to compare aggregate data across multiple 13 variants or genes from datasets such as ExAC or gnomad to one's own data, and the gold 14 standard will always be to compare sequenced cases to a large number of controls that have been 15 sequenced by the same group using identical methods. It is especially pertinent to be aware of 16 the coverage statistics, as some exons or sites may have poor or no coverage in some datasets. 17
18
In conclusion, here we present the first systematic analysis of the aggregated contribution of rare 19 variation in dystonia genes. Our analysis provides a statistical framework that can be used as the 20 field continues to develop more advanced and accurate abilities to ascertain the significance of 21 rare genetic variants in rare diseases. Such ongoing efforts include in vitro functional 22 phenotyping and the assembly of genotype-phenotype clinical databases (MDSgene) [41, 42] . 23
Our findings provide an easily accessible resource (Table 3) and highlight the necessity of 1 considering general population frequencies when evaluating the significance of rare variants to 2 rare diseases. The approach, in principle, is also applicable to other rare diseases as genome 3 sequence data increasingly enter the equation of care for an individual patient. S1 Table. Approximate percent (%) ExAC samples with qualifying variants in each of the previously reported dystonia genes for the coding (C) and likely gene disrupting (LGD) models.
